Ocular angiogenesis: The role of growth factors

Acta Ophthalmologica Scandinavica

Volumn 84, Issue 3, 2006, Pages 282-288

  Kvanta, Anders ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

Age related macular degeneration; Angiogenesis; Choroidal neovascularization; Corneal neovascularization; Proliferative diabetic retinopathy; Retinal neovascularization

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ERYTHROPOIETIN; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN C; VASCULOTROPIN;

ANGIOGENESIS; CHOROID; CORNEA; CORNEA NEOVASCULARIZATION; HUMAN; OCULAR BLOOD VESSEL; PRIORITY JOURNAL; REGULATORY MECHANISM; RETINA; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; CORNEAL NEOVASCULARIZATION; GROWTH SUBSTANCES; HUMANS; RETINAL NEOVASCULARIZATION;

EID: 33646797394     PISSN: 13953907     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2006.00659.x     Document Type: Review

References (85)

1. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK & Yeo KT (1994): Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 188: 445-450.
2. Adamis AP, Shima DT, Yeo KT, Brown LF, Berse B, D'Amore PA & Folkman J (1993): Synthesis and secretion of vascular permeability factor/ vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 193: 631-638.
3. Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480-1487.
4. Aiello LP, Northrup JM, Keyt BA, Tkagi H, Ferrara N & King GL (1995a): Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113: 1538-1544.
5. Aiello LP, Pierce EA, Foley ED et al. (1995b): Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 92: 10457-10461.
6. Amano S, Rohan R, Kuroki M, Tolentino M & Adamis AP (1998): Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39: 18-22.
7. Ambati J, Ambati BK, Yoo SH, Ianchulev S & Adamis AP (2003): Age-related macular degeneration: Aetiology, pathogenesis and therapeutic strategies. Surv Ophthalmol 48: 257-293.
8. Becerra SP & Amaral J (2002): Erythropoietin -an endogenous retinal survival factor. N Engl J Med 347: 1968-1970.
9. Betsholtz C, Lindblom P & Gerhardt H (2005): Role of pericytes in vascular morphogenesis. EXS 94: 115-125.
10. Bhutto IA, McLeod DS, Hasegawa T, Kim SY, Merges C, Tong P & Lutty GA (2005): Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroids and eyes with age-related macular degeneration. Exp Eye Res 82: 99-110.
11. Bikfavli A & Han ZC (1994): Angiogenic factors are haematopoietic growth factors and vice versa. Leukemia 8: 523-529.
12. Cai W, Rook SL, Jiang ZY, Takahara N & Aiello LP (2000): Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth. Invest Ophthalmol Vis Sci 41: 1885-1893.
13. Carmeliet P (2003): Angiogenesis in health and disease. Nat Med 9: 653-660.
14. Carmeliet P & Jain JK (2000): Angiogenesis in cancer and other diseases. Nature 407: 249-257.
15. Carmeliet P, Moons L, Luttun A et al. (2001): Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583.
16. Chang JH, Gabison EE, Kato T & Azar DT (2001): Corneal neovascularization. Curr Opin Ophthalmol 12: 242-249.
17. Cui JZ, Kimura H, Spee C, Thumann G, Hintin DR & Ryna SJ (2000): Natural history of choroidal neovascularization induced by vascular endothelial growth factor in the primate. Graefes Arch Clin Exp Ophthalmol 238: 326-333.
18. Cursiefen C, Cao J, Chen L et al. (2004b): Inhibition of haemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci 45: 2666-2673.
19. Cursiefen C, Chen L, Borges LP et al. (2004a): VEGF-A stimulates lymphangiogenesis and haemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113: 1040-1050.
20. Cursiefen C, Rummelt C & Kuchle M (2000): Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta-1 in human corneas with neovascularization. Cornea 19: 526-533.
21. Danis RP & Bingaman DP (1997): Insulin-like growth factor-1 retinal microangiopathy in the pig eye. Ophthalmology 104: 1661-1669.
22. Dills DG, Moss SE, Klein R & Klein BE (1991): Association of elevated IGF-1 levels with increased retinopathy in late-onset diabetes. Diabetes 40: 1725-1730.
23. Enge M, Bjarnegård M, Gerhardt HC et al. (2002): Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. EMBO J 16: 4307-4316.
24. Ferrara N, Gerber HP & LeCouter J (2003): The biology of VEGF and its receptors. Nat Med 9: 669-676.
25. Folkman J (1971T: Tumour angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1185.
26. Frank RN, Amin RH, Eliott D, Puklin JE & Abrams GW (1996): Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122: 393-403.
27. Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E, Schatz H & Derwahl M (2000): Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 108: 106-109.
28. Gonzales CR & VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group (2005): Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis. Retina 25: 815-827.
29. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR & VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004): Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351: 2805-2816.
30. Grant MB, Russel B, Fitzgerald C & Merimee TJ (1986): Insulin-like growth factors in vitreous: Studies in control and diabetic subjects with neovascularization. Diabetes 35: 416-420.
31. Hammes H-P, Lin J, Renner O, Shani M, Lundqvist A, Betsholtz C, Brownlee M & Deutch U (2002): Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 51: 3107-3112.
32. Hangai M, Moon YS, Kitaya N, Chan CK, Wu D-Y, Peters KG, Ryan SJ & Hinton DR (2001a): Systemically expressed soluble Tie-2 inhibits intraocular neovascularization. Hum Gene Ther 12: 1311-1321.
33. Hangai M, Mutata T, Miyawaki N, Spee C, Lim JI, He S, Hinton DR & Ryan SJ (2001b): Angiopoietin-1 upregulation by vascular endothelial growth factor in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 42: 1617-1625.
34. Hellstrom A, Perruzzi C, Ju M et al. (2001): Low IGF-1 suppresses VEGF-survival signalling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 98: 5804-5808.
35. Hera R, Keramidas M, Peoc'h M, Mouillon M, Romanet JP & Feige JJ (2005): Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. Am J Ophthalmol 139: 589-596.
36. Hernandez C, Carrasco E, Garcia-Arumi J, Maria Segera R & Simo (2004): Intravitreous levels of hepatocyte growth factor/scatter factor and vascular adhesion molecule-1 in the vitreous fluid of diabetic patients with proliferative retinopathy. Diabetes Metab 30: 341-346.
37. Ishibashi T, Hata Y, Yoshikawa H, Nakagawa K, Sueishi K & Inomata H (1997): Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 235: 159-167.
38. Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, McLeod D & Boulton M (1998): Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 78: 109-116.
39. Kinose F, Roscilli G, Lamartina S et al. (2005): Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor. Mol Vis 27: 366-373.
40. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S & de Jong PT (1997): Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81: 154-162.
41. Krantz SB (1991): Erythropoietin. Blood 77: 419-434.
42. Krzystolik MG, Afshari M, Adamis AP et al. (2002): Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120: 338-346.
43. Kvanta A (1995): Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr Eye Res 14: 1015-1020.
44. Kvanta A, Algvere PV, Berglin L & Seregard S (1996): Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 37: 1929-1934.
45. Kvanta A, Sarman S, Fagerholm P, Seregard S & Steen B (2000): Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70: 419-428.
46. Kwak N, Okamoto N, Wood JM & Campochiaro PA (2000): VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci 41: 3158-3164.
47. Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ, Kovesdi I & Rakoczy PE (2001): Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 12: 1299-1310.
48. Lai CM, Spilsbury K, Brankov M, Zaknich & Rakoczy PE (2002): Inhibition of corneal neovascularization by recombinant adenovirus mediated antisense VEGF RNA. Exp Eye Res 75: 625-634.
49. Lambooij AC, van Wely KH, Lindenberg-Kortleve DJ, Kuijpers RW, Kliffen M & Mooy CM (2003): Insulin-like growth factor-1 and its receptor in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 44: 2192-2198.
50. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A & Rahimi N (2000): Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 156: 1337-1344.
51. Leung DW, Cachianes G, Kuang WJ, Goeddel DV & Ferrara N (1989): Vascular endothelial growth factor is a secreted angiogenic mitigen. Science 246: 1306-1309.
52. Lopez PF, Sippy BD, Lambert HM, Thach AB & Hinton DR (1996): Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37: 855-868.
53. Malecaze F, Clamans S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F & Plouet J (1994): Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112: 1476-1482.
54. Merimee TJ, Zapf J & Froesch ER (1983): Insulin-like growth factors: studies in diabetics with and without retinopathy. N Engl J Med 309: 527-530.
55. Miller JW, Adamis AP, Shima DT et al. (1994): Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574-584.
56. Oshima Y, Oshima S, Nambu H et al. (2004): Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization. J Cell Physiol 201: 393-400.
57. Oshima Y, Oshima S, Nambu H et al. (2005): Different effects of angiopoietin-2 in different vascular beds: New vessels are most sensitive. FASEB J 19: 963-965.
58. Phillip W, Speicher L & Humpel C (2000): Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41: 2514-2522.
59. Pierce EA, Avery RL, Foley ED, Aiello LP & Smith LEH (1995): Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A 92: 905-909.
60. Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF & Adamis AP (2004): Insulin-like growth factor-1 plays a pathogenetic role in diabetic retinopathy. Am J Pathol 165: 457-469.
61. Rakic J-M, Lambert V, Devy L et al. (2003): Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3186-3193.
62. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennet J & Tolentino MJ (2003): Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 30: 210-216.
63. Robbins SG, Mixon KN, Wilson DJ, Hart CE, Robertson JE, Westra I, Planck SR & Rosenbaum JT (1994): Platelet-derived growth factor ligands and receptors immunolocalized in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 35: 3649-3663.
64. Robinson GGS, Pierce EA, Rook SL, Foley E, Webb L & Smith LE (1996): Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 93: 4851-4856.
65. Rosenthal R, Wohlleben H, Malek G, Schlichting L, Thieme H, Bowes Rickman C & Strauss O (2004): Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration. Biochem Biophys Res Commun 323: 1203-1208.
66. Senger DR, Perruzzi CA, Feder J & Dvorak HF (1986): A highly conserved vascular permeability factor secreted by a variety of human and rodent tumour cell lines. Cancer Res 46: 5629-5632.
67. Shih S-C, Ju M, Liu N & Smith LEH (2003): Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 112: 50-57.
68. Shinoda K, Ishida S, Kawashima S, Wakabayashi T, Matsuzaki T, Takayama M, Shinmura K & Yamada M (1999): Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol 83: 763-764.
69. Shweiki D, Itin A, Soffer D & Keshet E (1992): Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845.
70. Simpson DA, Murphy GM, Bhaduri T, Gardiner TA, Archer DB & Stitt AW (1999): Expression of VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun 262: 333-340.
71. Singh N, Amin S, Richter E et al. (2005a): Flt-1 intraceptor inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 46: 1647-1652.
72. Singh N, Macnamara E, Rashid S, Ambati J, Kontos CD, Higgins E & Ambati BK (2005b): Systemic soluble Tie-2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun 332: 194-199.
73. Smith LE, Kopchick JJ, Chen W et al. (1997): Essential role of growth hormone in ischaemia-induced retinal neovascularization. Science 276: 1706-1709.
74. Takagi H, Koyama S, Seike H, Oh H, Otani A, Matsumura M & Honda Y (2003): Potential role of the angiopoietin/Tie-2 system in ischaemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci 44: 393-402.
75. Takeda A, Hata Y, Shiose S, Sassa Y, Honda M, Fujisawa K, Sakamoto T & Ishibashi T (2003): Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol 241: 765-772.
76. Tezel TH, Bora NS & Kaplan HJ (2004): Pathogenesis of age-related macular degeneration. Trends Mol Med 10: 417-420.
77. Vinores SA, Xiao WH, Aslam S et al. (2005): Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol 206: 749-758.
78. Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M & Miller SS (2003): AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in the rat. Invest Ophthalmol Vis Sci 44: 781-790.
79. Watanabe D, Suzuma K, Matsui S et al. (2005): Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353: 782-792.
80. Wilkinson-Berka JL, Babic S, De Gooyer T, Stitt AW, Jaworski K, Ong LG, Kelly DJ & Gilbert RE (2004): Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischaemic retinopathy. Am J Pathol 164: 1263-1273.
81. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ & Holash J (2000): Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
82. Yi X, Ogata N, Komada M, Yamamoto C, Takahashi K, Omori K & Uyama M (1997): Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefes Arch Clin Exp Ophthalmol 235: 313-319.
83. Yonekura H, Sakurai S, Liu X et al. (1999): Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem 274: 35172-35178.
84. Zhao B, Cai J & Boulton M (2003): Expression of placenta growth factor is regulated by both VEGF and hyperglycaemia via VEGFR-2. Microvasc Res 68: 239-246.
85. Zhou J, Pham L, Zhang N, He S, Gamulescu MA, Spee C, Ryan SJ & Hinton DR (2005): Neutrophils promote experimental choroidal neovascularization. Mol Vis 11: 414-424.